RA
VRTX icon

Riversedge Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Riversedge Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$555K Buy
1,061
+68
+7% +$34.8K 0.07% 133
2026
Q2 		$493K Buy
+993
New +$440K 0.07% 124

Other funds holding VRTX

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GGS
Galvin Gaustad & Stein Scottsdale, Arizona $1.33B AUM 13.15% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
CFG
Cooper Financial Group Irvine, California $1.26B AUM 21.18% 1-Year Est. Return

Riversedge Advisors's VRTX Position: Q3 2026 in Review

Riversedge Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 6.8% in Q3 2026, buying an estimated $34.8K and bringing the position to 1,061 shares worth $555K. The position accounts for 0.07% of the portfolio, ranked #133.

Riversedge Advisors first reported a position in VRTX in Q2 2026 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Riversedge Advisors held 1,061 shares of Vertex Pharmaceuticals worth $555K as of Q3 2026.
  • Riversedge Advisors bought 68 Vertex Pharmaceuticals shares in Q3 2026, an estimated $34.8K.
  • Vertex Pharmaceuticals made up 0.07% of Riversedge Advisors's portfolio in Q3 2026, its #133 holding.
  • Riversedge Advisors first reported a position in Vertex Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Riversedge Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.